Sort by 'likes'
Waldenstrom’s Macroglobulinemia: Advances in Treatments
Waldenstrom’s macroglobulinemia (WM) is a lymphoma, or cancer of the lymphatic system. The disease begins in a type of white blood cell called a B-lymphocyte, which normally matures into a plasma cell. In WM, there is a malignant change to…
Off-the-shelf Immune Drug for Aggressive Multiple Myeloma: Teclistamab
U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for teclistamab in the treatment of relapsed or refractory multiple myeloma. This follows a PRIME (PRIority MEdicines) designation from the European Medicines Agency (EMA) received earlier this year. …
Diagnosing Aggressive Forms of Prostate Cancer With New Imaging Tests and Biomarkers
On this show we have the Associate Director, Department of Urology, Roswell Park Cancer Institute Dr. James Mohler discussing the recent NCCN guidelines for prostate cancer treatment and the latest research available to us that can help diagnose high risk…
What’s New in Multiple Myeloma Management?
Multiple myeloma is diagnosed in over 100,000 patients each year worldwide. The FDA recently granted accelerated approval to Teclistamab, the first bispecific B-cell maturation (BCMA)-directed CD3 T-cell engager. The therapeutic armamentarium for myeloma now includes alkylating agents, corticosteroids, deacetylase inhibitors,…
The New Optimism of Combination Therapies in Multiple Myeloma Treatment.
Clinical trials of new combination therapies are showing promising results and can be a game changer in myeloma treatment - Combining standard drugs with monoclonal antibodies, t-cell therapies with stem cell transplants, myeloma vaccine combinations and more. We are talking…